Securities code: Shandong Sito Bio-Technology Co.Ltd(300583) securities abbreviation: Shandong Sito Bio-Technology Co.Ltd(300583) Announcement No.: 2022011 Shandong Sito Bio-Technology Co.Ltd(300583)
On the termination of the issue of A-Shares to specific objects in 2021 and withdrawal
Announcement of application documents
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Shandong Sito Bio-Technology Co.Ltd(300583) (hereinafter referred to as “the company”) held the 7th Meeting of the 3rd board of directors and the 7th Meeting of the 3rd board of supervisors on April 5, 2022, deliberated and adopted the proposal on terminating the issue of A-Shares to specific objects in 2021 and withdrawing the application documents, Agree to terminate the company’s issue of A-Shares to specific objects in 2021 and apply to Shenzhen Stock Exchange (hereinafter referred to as “Shenzhen Stock Exchange”) to withdraw the application documents for issuing A-Shares to specific objects. The relevant information is hereby announced as follows:
1、 Basic information of issuing A-Shares to specific objects in 2021
The company held the third meeting of the third board of directors and the third meeting of the third board of supervisors on July 16, 2021, and the first extraordinary general meeting of shareholders in 2021 on August 2, 2021, which deliberated and approved the proposal on the company’s plan to issue A-Shares to specific objects in 2021 and other relevant proposals. The general meeting of shareholders authorized the board of directors to handle matters related to the issuance of shares to specific objects.
On August 24, 2021, the company received the notice on accepting the application documents of Shandong Sito Bio-Technology Co.Ltd(300583) issuing shares to specific objects issued by Shenzhen Stock Exchange (szss [2021] No. 403), and Shenzhen Stock Exchange decided to accept it.
On October 15, 2021, the company held the fifth meeting of the third board of directors and the fifth meeting of the third board of supervisors, deliberated and adopted the proposal on adjusting the company’s plan to issue A-Shares to specific objects in 2021 and other relevant proposals.
The inquiry letter of the company on the examination of the application for the issuance of shares issued by the Shenzhen Stock Exchange on October 1, 2023 (the inquiry letter on the examination of the specific issuance object was issued to the Shenzhen Stock Exchange on October 1, 2023), respectively Inquiry letter on the third round of examination of Shandong Sito Bio-Technology Co.Ltd(300583) application for issuing shares to specific objects (examination letter [2021] No. 020301). The company has completed the reply and disclosure of the audit inquiry letter together with the intermediary.
On January 5, 2022, the company’s application for issuing shares to specific objects was approved by the listing audit center of Shenzhen Stock Exchange.
For details of the above, please refer to cninfo.com, the gem information disclosure website designated by the CSRC info. com. cn. Relevant announcements of disclosure.
2、 Reasons for terminating the issue of A-Shares to specific objects in 2021 and withdrawing the application documents
In view of the changes in the current capital market environment and financing opportunities, combined with the actual situation of the company, future development planning and other factors, after careful analysis and repeated communication with intermediaries, the company decided to terminate the issue of shares to specific objects and apply to Shenzhen stock exchange for withdrawal of relevant application documents.
3、 The impact of terminating the issue of A-Shares to specific objects in 2021 and withdrawing the application documents on the company
At present, all businesses of the company are operating normally. Terminating the issue of shares to specific objects and withdrawing the application documents will not have a significant adverse impact on the daily production and operation of the company, and there is no situation that damages the interests of the company and all shareholders, especially minority shareholders.
4、 Terminate the deliberation procedure of issuing A-Shares to specific objects in 2021 and withdrawing the application documents 1. Deliberation of the board of directors
On April 5, 2022, the company held the seventh meeting of the third board of directors, deliberated and approved the proposal on terminating the issue of A-Shares to specific objects in 2021 and withdrawing the application documents, agreed to terminate the issue of A-Shares to specific objects in 2021 and applied to Shenzhen stock exchange for withdrawing the relevant application documents.
The company’s first extraordinary general meeting of shareholders in 2021 authorized the board of directors to handle matters related to the issuance of shares to specific objects. Therefore, the termination of the issuance of shares to specific objects does not need to be submitted to the general meeting of shareholders for deliberation. 2. Deliberation of the board of supervisors
On April 5, 2022, the company held the 7th Meeting of the 3rd board of supervisors, deliberated and approved the proposal on terminating the issue of A-Shares to specific objects in 2021 and withdrawing the application documents, agreed to terminate the issue of A-Shares to specific objects in 2021 and applied to Shenzhen stock exchange for withdrawing the relevant application documents.
3. Prior approval opinions of independent directors
The termination of the issue of A-Shares to specific objects in 2021 is a decision made in combination with the changes of the current capital market environment and financing opportunities, and comprehensively considering the actual situation of the company, future development planning and other factors. It is understood that the company’s current business operations are normal, and the termination of the issuance of shares to specific objects will not have a significant adverse impact on the company’s daily production and operation, and there is no damage to the interests of the company and shareholders, especially minority shareholders. Therefore, all independent directors agreed to submit this proposal to the seventh meeting of the third board of directors of the company for deliberation after prior deliberation.
4. Opinions of independent directors
The company’s decision to terminate the issue of A-Shares to specific objects in 2021 and withdraw the application documents is a decision made in combination with the current capital market environment, financing opportunities and other changes, taking into account the actual situation of the company, future development planning and other factors. At present, all businesses of the company operate normally. The withdrawal of relevant application documents will not have a significant impact on the daily production and operation of the company, and there is no situation that damages the interests of the company and all shareholders, especially minority shareholders. The deliberation procedures of the board of directors of the company on this matter comply with the provisions of relevant laws and regulations, normative documents and the articles of association. Therefore, all independent directors unanimously agreed that the company would terminate the issue of A-Shares to specific objects in 2021 and withdraw the application documents.
5、 Documents for future reference
1. Resolutions of the seventh meeting of the third board of directors of the company;
2. Prior approval opinions of the independent directors of the company on matters related to the seventh meeting of the third board of directors of the company;
3. Independent opinions of the company’s independent directors on matters related to the seventh meeting of the third board of directors; 4. Resolution of the 7th Meeting of the 3rd board of supervisors of the company.
It is hereby announced.
Shandong Sito Bio-Technology Co.Ltd(300583) board of directors
April 6, 2002
